724 - A phase 2b, randomized, double-blinded, parallel-group, placebo-controlled study to evaluate the efficacy and safety of rezpegaldesleukin in adults with severe to very-severe alopecia areata
David Rosmarin(Indiana University School of Medicine), Charles Lynde(University of Toronto), Stephen M. Schleicher(Tennessee Oncology), Jacek Zdybski(Akademii Nauk Stosowanych im. Józefa Gołuchowskiego), Sohail S. Chaudhry(Nektar Therapeutics (United States)), Bartłomiej Kwiek(Uczelnia Łazarskiego), Timothy Rodgers(Center for Clinical Research (United States)), Agnieszka Owczarczyk‐Saczonek(University of Warmia and Mazury in Olsztyn), Adam Reich(Rzeszów University of Technology), Edward Lain(Houston Institute for Clinical Research), Mary Tagliaferri(Nektar Therapeutics (United States)), Lucinda M Elko-Simms(Nektar Therapeutics (United States)), Brian Lewis(Nektar Therapeutics (United States)), Neil S. Sadick(Cornell University), Christie Fanton(Nektar Therapeutics (United States)), Wojciech Baran(Wroclaw Medical University), Heng Xu(Nektar Therapeutics (United States)), Zachary Lee(Nektar Therapeutics (United States)), Yi Liu(Nektar Therapeutics (United States)), Michal Torz, Katie Mellskog(Nektar Therapeutics (United States)), Jacek C Szepietowski(Wroclaw Medical University), Lawrence Osman, Jonathan Zalevsky(Nektar Therapeutics (United States))
Cited by 0
Related Papers
Definition of treatment goals for moderate to severe psoriasis: a European consensus
|Archives of Dermatological Research|2010|892
β-Arrestin–Dependent Endocytosis of Proteinase-Activated Receptor 2 Is Required for Intracellular Targeting of Activated Erk1/2
|The Journal of Cell Biology|2000|816
Enhanced antibody half-life improves in vivo activity
|Nature Biotechnology|2010|654